Certara, Inc. Stock News

Certara, Inc. provides biosimulation software and services to the biotech and biopharma industry. The company is enjoying sales growth from its software division in the mid-teen but service growth is

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 a

Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor co

Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations Programs focus on use of

Certara Inc. CERT, -2.56% stock was down 14.6% in premarket trades on Thursday after the biotech software company missed Wall Street's adjusted earnings and revenue targets and said its 2023 profit wo

Certara Inc. (NASDAQ:CERT ) Q2 2023 Results Conference Call August 9, 2023 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO and Director John Gallagher - Chief Financial Offic

PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023

PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Heal

Certara, Inc. (NASDAQ:CERT ) Q1 2023 Results Conference Call May 8, 2023 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO John Gallagher - CFO Conference Call Participants Dav

We have narrowed our search to five stocks that are set to report first-quarter 2023 earnings results. These are: SHAK, WING, AMK, PRI and CERT.

PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

MINISO Group Holding Limited (NYSE: MNSO), PDF Solutions Inc. (NASDAQ: PDFS), and Certara Inc. (NASDAQ: CERT) are relatively unknown stocks currently showing strong price momentum.